Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.
Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ. Goddard J, et al. Among authors: rabelink tj. Circulation. 2004 Mar 9;109(9):1186-93. doi: 10.1161/01.CIR.0000118499.69469.51. Epub 2004 Feb 23. Circulation. 2004. PMID: 14981006 Clinical Trial.
Endothelin: new discoveries and rapid progress in the clinic.
Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Webb DJ, et al. Among authors: rabelink tj. Trends Pharmacol Sci. 1998 Jan;19(1):5-8. doi: 10.1016/s0165-6147(97)01144-9. Trends Pharmacol Sci. 1998. PMID: 9509892
Arterial baroreflex control of renal hemodynamics in humans.
van Tilborg KA, Rabelink TJ, van Rijn HJ, Boomsma F, Koomans HA. van Tilborg KA, et al. Among authors: rabelink tj. Circulation. 1994 Oct;90(4):1883-90. doi: 10.1161/01.cir.90.4.1883. Circulation. 1994. PMID: 7923676 Clinical Trial.
Decreased Expression of Vascular Endothelial Growth Factor Receptor 1 Contributes to the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2.
Thalgott JH, Dos-Santos-Luis D, Hosman AE, Martin S, Lamandé N, Bracquart D, Srun S, Galaris G, de Boer HC, Tual-Chalot S, Kroon S, Arthur HM, Cao Y, Snijder RJ, Disch F, Mager JJ, Rabelink TJ, Mummery CL, Raymond K, Lebrin F. Thalgott JH, et al. Among authors: rabelink tj. Circulation. 2018 Dec 4;138(23):2698-2712. doi: 10.1161/CIRCULATIONAHA.117.033062. Circulation. 2018. PMID: 30571259
521 results